Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Appropriate without clinical oversight
The market is being reshaped by 6 forces: Market size: $94B today $216B+ by 2035 (8.8% CAGR) Oral GLP-1s just got FDA approval eliminating the needle barrier for millions WHO officially recommends GLP-1s for long-term obesity treatment (Dec 2025) Novo Nordisk slashed Ozempic/Wegovy prices by up to 70% unlocking mass adoption Next-gen tri-agonists (retatrutide) showing 28.7% weight loss in trials Only ~7% diabetes penetration and ~2% obesity penetration the growth runway is massive The ripple effects extend far beyond pharma: Food & beverage: $30$55B annual revenue at risk as GLP-1 users cut calories by 21% Employers: 77% of large companies say managing GLP-1 costs is a top priority Eli Lilly became the first pharma company to surpass $1 trillion market cap ~150 GLP-1 drugs now in development globally 2530 million Americans projected on GLP-1 therapy by 2030 The question isnt whether GLP-1s will reshape global healthcare
Elsevier Academic Press, London, p IiiiIxxxvi Nery F, Buchanan CE, Harteveld AA, Odudu A, Bane O, Cox EF, Derlin K, Gach HM, Golay X, Gutberlet M, Laustsen C, Ljimani A, Madhuranthakam AJ, Pedrosa I, Prasad PV, Robson PM, Sharma K, Sourbron S, Taso M, Thomas DL, Wang DJJ, Zhang JL, Alsop DC, Fain SB, Francis ST, Fernndez-Seara MA (2020) Consensus-based technical recommendations for clinical translation of renal ASL MRI
How do TUDCA supplements work
